Home >> Research Area >>Natural Products>>Triterpenoids>> (20S)-Protopanaxdiol

(20S)-Protopanaxdiol

CAS# 30636-90-9

(20S)-Protopanaxdiol

Catalog No. BCN1254----Order now to get a substantial discount!

Product Name & Size Price Stock
(20S)-Protopanaxdiol: 5mg $12 In Stock
(20S)-Protopanaxdiol: 10mg Please Inquire In Stock
(20S)-Protopanaxdiol: 20mg Please Inquire Please Inquire
(20S)-Protopanaxdiol: 50mg Please Inquire Please Inquire
(20S)-Protopanaxdiol: 100mg Please Inquire Please Inquire
(20S)-Protopanaxdiol: 200mg Please Inquire Please Inquire
(20S)-Protopanaxdiol: 500mg Please Inquire Please Inquire
(20S)-Protopanaxdiol: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of (20S)-Protopanaxdiol

Number of papers citing our products

Chemical structure

(20S)-Protopanaxdiol

3D structure

Chemical Properties of (20S)-Protopanaxdiol

Cas No. 30636-90-9 SDF Download SDF
PubChem ID 11213350 Appearance White powder
Formula C30H52O3 M.Wt 460.7
Type of Compound Triterpenoids Storage Desiccate at -20°C
Synonyms 20-Epiprotopanaxadiol; 20(S)-APPD
Solubility DMSO : ≥ 100 mg/mL (217.05 mM)
H2O : < 0.1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
Chemical Name (3S,5R,8R,9R,10R,12R,13R,14R,17S)-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,12-diol
SMILES CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)O)C)C)O)C)O)C
Standard InChIKey PYXFVCFISTUSOO-HKUCOEKDSA-N
Standard InChI InChI=1S/C30H52O3/c1-19(2)10-9-14-30(8,33)20-11-16-29(7)25(20)21(31)18-23-27(5)15-13-24(32)26(3,4)22(27)12-17-28(23,29)6/h10,20-25,31-33H,9,11-18H2,1-8H3/t20-,21+,22-,23+,24-,25-,27-,28+,29+,30-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of (20S)-Protopanaxdiol

The roots of Panax ginseng C. A. Mey.

Biological Activity of (20S)-Protopanaxdiol

Description20(S)-Protopanaxdiol may be a potential new P-gp inhibitor for cancer treatment, it may induce the apoptosis via the down-regulation of Bcl-2 protein and the up-regulation of γH2Ax protein expression; it may inhibit the proliferation of Siha cells via the up-regulating the expressions of p53, p21, and autophagy related gene Beclin 1and MAP1-LC3, and down-regulating the expression of cyclin-E.
Targetsp53 | p21 | Bcl-2/Bax | P-gp | Caspase | γH2Ax
In vitro

Inhibitory effect of 20(s)-protopanaxdiol on proliferation of Siha cells in vitro and its mechanism.[Reference: WebLink]

Journal of Jilin University, 2013, 39(05):909-12.

To observe the effect of (20S)-Protopanaxdiol(PPD)on the cell cycle of Siha cells in vitro and to detect the transcription and expressions of p53,p21and cyclin-E,and to clarify the mechanism of its inhibitory effect on proliferation of Siha cells.
METHODS AND RESULTS:
The Siha cells cultivated in vitro were treated with alcohol(negative control group)and 20μg·L-1 PPD(PPD group),respectively.The cell cycle was detected by FCM 48h after treatment.The mRNA and protein expressions of p53,p21and cyclin-E in Siha cells were analyzed by Real time PCR and Western blotting. Compared with negative control group,after treated with 20μg·L-1 PPD for 48h,the ratio of Siha cells at G0 /G1 phase was increased(P0.01),the blockage of G1 phase was obviously enhanced;the transcription and protein expressions of p53and p21were up-regulated(P0.01);while the transcription and expression of cyclin-E were significantly decreased(P0.01).
CONCLUSIONS:
PPD may inhibit the proliferation of Siha cells,and its mechanism may be related to up-regulating the expressions of p53and p21and down-regulating the expression of cyclin-E.

Protocol of (20S)-Protopanaxdiol

Kinase Assay

20S-protopanaxadiol inhibits P-glycoprotein in multidrug resistant cancer cells.[Pubmed: 19291609]

Planta Med. 2009 Aug;75(10):1124-8.

One of the major causes for cancer cells to resist current chemotherapy is attributed to the over-expression of P-glycoprotein (P-gp), resulting in insufficient drug delivery to the tumor sites.
METHODS AND RESULTS:
Protopanaxadiol ginsenosides Rg3 and Rh2 are known to induce apoptosis and significantly enhance the tumor inhibitory effects of chemotherapeutics in a synergistic fashion. One of the possible mechanisms is by blocking P-gp activity. The final deglycosylation metabolite of protopanaxadiols (PPDs) IN VIVO is (20S)-Protopanaxdiol (aglycone PPD, aPPD), which has also shown anticancer activity and synergy with chemotherapy drugs. In the present study, P-gp over-expressing cancer cells were utilized to test whether (20S)-Protopanaxdiol also inhibits P-gp activity. We found that (20S)-Protopanaxdiol caused similar cytotoxicity in P388adr cells as their parental non-MDR cells, suggesting that (20S)-Protopanaxdiol may not be a substrate of P-gp. On the other hand, the calcein AM efflux assay showed that (20S)-Protopanaxdiol was able to inhibit P-gp activity as potently as verapamil on MDR cells. The blockage of P-gp activity was highly reversible as wash-out of (20S)-Protopanaxdiol resulted in an immediate recovery of P-gp activity. Unlike verapamil, (20S)-Protopanaxdiol did not affect ATPase activity of P-gp suggesting a different mechanism of action.
CONCLUSIONS:
The above results indicate that (20S)-Protopanaxdiol , unlike its precursor ginsenosides Rg3 and Rh2, is not a substrate of P-gp. It is also the first time that (20S)-Protopanaxdiol has showed a reversible nature of its P-gp inhibition. In addition to its pro-apoptotic nature, (20S)-Protopanaxdiol may be a potential new P-gp inhibitor for cancer treatment.

Cell Research

Inductive effect of (20s)-proto-panaxdiol on apoptosis of human prostate cancer PC3 cells cultivated in vitro and its mechanism[Reference: WebLink]

Journal of Jilin University Medicine Edition, 2012, 38(3):482-5.

To study the effect of (20S)-Protopanaxdiol (PPD) on apoptosis of human prostate cancer PC3 cells cultivated in vitro, and to clarify the mechanism of its anticancer action.
METHODS AND RESULTS:
The PC3 cells cultivated in vitro were divided into control, and 20, 30, 40 μmol·L -1 PPD groups. The morphological changes of PC3 cells were observed under optical microscope after treated with PPD for 48 h. The proliferation inhibition of PC3 cells was detected by MTT method. The apoptosis of PC3 cells was detected by AO/EB staining and the expressions of Bax, Bcl-2 and γH2Ax proteins were analyzed by Western blotting. After treated with different doses of PPD, the PC3 cells were round, recovery, and broken. AO/EB staining found that the cells presented yellow-green. The inhibitory rates of proliferation of PC3 cells in various groups were increased compared with control group(P<0.05). The expression of Bcl-2 protein was down-regulated(P<0.05), the expression of Bax protein didn't change significantly, and the expression of γH2Ax protein was up-regulated (P < 0.05).
CONCLUSIONS:
PPD may induce the apoptosis of PC3 cells, and its mechanism may be related to the down-regulation of Bcl-2 protein and the up-regulation of γH2Ax protein expression.

(20S)-Protopanaxdiol Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

(20S)-Protopanaxdiol Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of (20S)-Protopanaxdiol

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1706 mL 10.853 mL 21.7061 mL 43.4122 mL 54.2652 mL
5 mM 0.4341 mL 2.1706 mL 4.3412 mL 8.6824 mL 10.853 mL
10 mM 0.2171 mL 1.0853 mL 2.1706 mL 4.3412 mL 5.4265 mL
50 mM 0.0434 mL 0.2171 mL 0.4341 mL 0.8682 mL 1.0853 mL
100 mM 0.0217 mL 0.1085 mL 0.2171 mL 0.4341 mL 0.5427 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on (20S)-Protopanaxdiol

(20S)-Protopanaxadiol (20-Epiprotopanaxadiol) is an aglycon metabolic derivative of the protopanaxadiol-type ginseng saponin; apoptosis inducer. IC50 value: Target: apoptosis inducer (20S)-Protopanaxadiol was used to induce cytotoxicity for two human glioma cell lines, SF188 and U87MG. For the SF188 cells, (20S)-Protopanaxadiol activated caspases-3, -8, -7, and -9 within 3 h and induced rapid apoptosis, which could be partially inhibited by a general caspase blocker and completely abolished when the caspase blocker was used in combination with an antioxidant. (20S)-Protopanaxadiol also induced cell death in U87MG cells but did not activate any caspases in these cells [1]. aPPD was able to inhibit P-gp activity as potently as verapamil on MDR cells. The blockage of P-gp activity was highly reversible as wash-out of aPPD resulted in an immediate recovery of P-gp activity. Unlike verapamil, aPPD did not affect ATPase activity of P-gp suggesting a different mechanism of action [2].

References:
[1]. Liu GY, et al. 20S-protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and -independent pathways. J Nat Prod. 2007 Feb;70(2):259-64. [2]. Zhao Y, et al. 20S-protopanaxadiol inhibits P-glycoprotein in multidrug resistant cancer cells. Planta Med. 2009 Aug;75(10):1124-8.

Featured Products
New Products
 

References on (20S)-Protopanaxdiol

20S-protopanaxadiol inhibits P-glycoprotein in multidrug resistant cancer cells.[Pubmed:19291609]

Planta Med. 2009 Aug;75(10):1124-8.

One of the major causes for cancer cells to resist current chemotherapy is attributed to the over-expression of P-glycoprotein (P-gp), resulting in insufficient drug delivery to the tumor sites. Protopanaxadiol ginsenosides Rg3 and Rh2 are known to induce apoptosis and significantly enhance the tumor inhibitory effects of chemotherapeutics in a synergistic fashion. One of the possible mechanisms is by blocking P-gp activity. The final deglycosylation metabolite of protopanaxadiols (PPDs) IN VIVO is 20S-protopapanaxadiol (aglycone PPD, aPPD), which has also shown anticancer activity and synergy with chemotherapy drugs. In the present study, P-gp over-expressing cancer cells were utilized to test whether aPPD also inhibits P-gp activity. We found that aPPD caused similar cytotoxicity in P388adr cells as their parental non-MDR cells, suggesting that aPPD may not be a substrate of P-gp. On the other hand, the calcein AM efflux assay showed that aPPD was able to inhibit P-gp activity as potently as verapamil on MDR cells. The blockage of P-gp activity was highly reversible as wash-out of aPPD resulted in an immediate recovery of P-gp activity. Unlike verapamil, aPPD did not affect ATPase activity of P-gp suggesting a different mechanism of action. The above results indicate that aPPD, unlike its precursor ginsenosides Rg3 and Rh2, is not a substrate of P-gp. It is also the first time that aPPD has showed a reversible nature of its P-gp inhibition. In addition to its pro-apoptotic nature, aPPD may be a potential new P-gp inhibitor for cancer treatment.

Description

(20S)-Protopanaxadiol (20-Epiprotopanaxadiol) is an aglycon metabolic derivative of the protopanaxadiol-type ginseng saponin; apoptosis inducer.

Keywords:

(20S)-Protopanaxdiol,30636-90-9,20-Epiprotopanaxadiol; 20(S)-APPD,Natural Products, buy (20S)-Protopanaxdiol , (20S)-Protopanaxdiol supplier , purchase (20S)-Protopanaxdiol , (20S)-Protopanaxdiol cost , (20S)-Protopanaxdiol manufacturer , order (20S)-Protopanaxdiol , high purity (20S)-Protopanaxdiol

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: